For example, the AKT pathway has been described as a potential drug intervention in clear cell renal carcinoma:45AKT2 gene belongs to the signature of cluster 3 (comprising LGG, KIRC, and KIRP), it is somatically mutated in the tumours of cluster 3 and it has been annotated as drug-target according to the DrugBank database. The gene discussed is AKT1; the disease is clear cell renal carcinoma.